Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil E Kay

Showing results (131-140 of 325) with videos related to

Pageof 33
Sort By:
Leukemia & Lymphoma|February 9, 2018
Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect<sup>®</sup> CLL cohort studyChristopher R Flowers, Chadi Nabhan, Neil E Kay, et al.
Cancer Genetics and Cytogenetics|December 16, 2010
Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapyNeil E Kay, Jeanette E Eckel-Passow, Esteban Braggio, et al.
Cancer Genetics and Cytogenetics|April 25, 2006
Metaphase cells with normal G-bands have cryptic interstitial deletions in 13q14 detectable by fluorescence in situ hybridization in B-cell chronic lymphocytic leukemiaKimberly J Stockero, Stephanie R Fink, Stephanie A Smoley, et al.
Blood|May 6, 2009
De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experienceConstantine S Tam, Tait D Shanafelt, William G Wierda, et al.
Haematologica|August 6, 2013
Chronic lymphocytic leukemia in young (≤ 55 years) patients: a comprehensive analysis of prognostic factors and outcomesSameer A Parikh, Kari G Rabe, Neil E Kay, et al.
British Journal of Haematology|April 8, 2017
CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemiaPaolo Strati, Sameer A Parikh, Kari G Chaffee, et al.
British Journal of Haematology|November 10, 2009
A comprehensive evaluation of the prognostic significance of 13q deletions in patients with B-chronic lymphocytic leukaemiaDaniel L Van Dyke, Tait D Shanafelt, Timothy G Call, et al.
Blood|October 12, 2023
Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trialDespoina Papazoglou, Xin Victoria Wang, Tait D Shanafelt, et al.
British Journal of Haematology|October 12, 2013
Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosisWei Ding, Tait D Shanafelt, Connie E Lesnick, et al.
Molecular Cancer Therapeutics|August 13, 2015
Sphingosine Kinase-1 Protects Multiple Myeloma from Apoptosis Driven by Cancer-Specific Inhibition of RTKsShuntaro Tsukamoto, Yuhui Huang, Motofumi Kumazoe, et al.
Pageof 33

Showing results (131-140 of 325) with videos related to

Sort By:
Pageof 33
Leukemia & Lymphoma|February 9, 2018
Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect<sup>®</sup> CLL cohort studyChristopher R Flowers, Chadi Nabhan, Neil E Kay, et al.
Cancer Genetics and Cytogenetics|December 16, 2010
Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapyNeil E Kay, Jeanette E Eckel-Passow, Esteban Braggio, et al.
Cancer Genetics and Cytogenetics|April 25, 2006
Metaphase cells with normal G-bands have cryptic interstitial deletions in 13q14 detectable by fluorescence in situ hybridization in B-cell chronic lymphocytic leukemiaKimberly J Stockero, Stephanie R Fink, Stephanie A Smoley, et al.
Blood|May 6, 2009
De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experienceConstantine S Tam, Tait D Shanafelt, William G Wierda, et al.
Haematologica|August 6, 2013
Chronic lymphocytic leukemia in young (≤ 55 years) patients: a comprehensive analysis of prognostic factors and outcomesSameer A Parikh, Kari G Rabe, Neil E Kay, et al.
British Journal of Haematology|April 8, 2017
CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemiaPaolo Strati, Sameer A Parikh, Kari G Chaffee, et al.
British Journal of Haematology|November 10, 2009
A comprehensive evaluation of the prognostic significance of 13q deletions in patients with B-chronic lymphocytic leukaemiaDaniel L Van Dyke, Tait D Shanafelt, Timothy G Call, et al.
Blood|October 12, 2023
Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trialDespoina Papazoglou, Xin Victoria Wang, Tait D Shanafelt, et al.
British Journal of Haematology|October 12, 2013
Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosisWei Ding, Tait D Shanafelt, Connie E Lesnick, et al.
Molecular Cancer Therapeutics|August 13, 2015
Sphingosine Kinase-1 Protects Multiple Myeloma from Apoptosis Driven by Cancer-Specific Inhibition of RTKsShuntaro Tsukamoto, Yuhui Huang, Motofumi Kumazoe, et al.
Pageof 33